(NASDAQ:SPPI) SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead...
Related Questions
Will the reopening of the lead plaintiff process cause short‑term volatility in SPPI's stock price?
How might the potential settlement size or legal outcome affect SPPI's valuation and future earnings forecasts?
What precedent does this lawsuit set for other biotech firms and could it influence investor sentiment toward the sector?